The basic mechanism of rhAd-p53 reagent is as follows [37]: Inhibiting tumor growth by cell cycle arrest and inducing programmed cell death; (ii) Inhibiting tumor growth by cell cycle arrest and inducing programmed cell death; (ii) Enhance chemotherapy-induced cell cycle arrest and apoptosis; (iii) Stimulate the body to produce anti-tumor immunity, such as a large number of immune cells gathered in the local injection site of the tumor. The gene discussed is TP53; the disease is neoplasm.